Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
·37m ago
Source: Oncodaily
Read the original article This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment?
An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
This article is an excerpt. To read the full content, visit the original source. Oncodaily
Reactions
Related articles
Digital twin technology shows ability to personalize ablation planning - Cardiovascular Business
Cardiovascular Business·
0 comments
No comments yet. Be the first to share your thoughts!